Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
Key takeaways
- JNJ’s new data show RYBREVANT is safer when given subcutaneously and more effective in a tough NSCLC subgroup, but the market remains wary.
- 214 U.S. patients
- 8.3 months median follow‑up
- 8% discontinuation due to adverse events
What happened
Johnson & Johnson (JNJ) reported new Phase 2b COPERNICUS data showing the subcutaneous combo of RYBREVANT FASPRO and LAZCLUZE has a low toxicity profile in 214 U.S. patients with untreated EGFR‑mutated NSCLC, with only 8 % discontinuing due to adverse events. The study also released final Phase 3 PAPILLON results, where intravenous RYBREVANT plus chemo raised median overall survival to 34.3 months versus 27.9 months for chemo alone, a 6.4‑month gain and a 43 % death‑risk reduction after…
Why it matters
The safety data suggest the subcutaneous route may improve patient tolerability compared to the earlier intravenous regimen, potentially widening the drug’s clinical use. The survival benefit in the PAPILLON trial confirms RYBREVANT’s efficacy in a hard‑to‑treat EGFR exon 20 insertion cohort, strengthening its…
Short-term and longer-term
Short-term. Short‑term traders should watch JNJ’s stock around the next earnings release for any guidance updates on RYBREVANT sales.
Longer-term. Over the next 12–18 months, investors should monitor JNJ’s ability to scale RYBREVANT production and secure reimbursement for the subcutaneous formulation.